Mac Beer is an executive with more than 25 years of experience in commercialization and development in Pharmaceuticals, biotechnology, and diagnostic industries. His most recent job was as a member of the board and Chief executive Officer of Aegorian Pharmaceuticals. While here he helped take the company public. In October 2010, he oversaw the marketing and successful launch of JUXTAPID. This was a prescription used by those adults with homozygous hypercholesterolemia to reduce cholesterol.
Before joining Aegorian, Mac was the founder and Chief Executive Officer of ViaCell. This is a biotechnology company that deals with the preservation and collection of umbilical cords blood stem cells. He led the company to a robust commercial organization and rapidly growing company for a total period of seven years. He had earlier held several positions with Genzyme, a care company that develops treatments for diseases that are difficult to treat and diagnose. He holds a Bachelor of Science degree from Miami University in Ohio.
Digital therapeutics Revonia has a plan to improve its product development, commercialization plans, corporate hires, and clinical trials. It has therefore raised $42.3 million to finance therapy and diagnostic devices for women having pelvic floor disorders. This funding includes $10 million in venture debt and $32.3 million in series B equity. This was led by Ascension Ventures and Perceptive Advisors, together with OSF Ventures, Inova Strategic Investments, Longwood Fund, Western Technology Investment, and Cormorant Asset Management. The mix of new and existing financial investors and the partnership with leading integrated health networks is aligned with Revonia’s commercial and clinical vision.
Rivonia’s FDA-Bluetooth device and cleared training program directs and isolates the movement of the levator plate muscles through coaching sessions and real-time visualizations via a smartphone app for pelvic muscle training at home. The company’s pipeline also includes its cleared device, the Leva and extended wearable. The symptoms of pelvic floor disorders include pressure, incomplete emptying and urinary incontinence. If the company combines its propriety sensor and innovative technologies to form factors with a digital platform, it will drive greater understanding of pelvic disorders. This will also give their customers valuable data on new treatment options. All this will lower the cost of healthcare. The ultimate goal of Rivonia is to lower the cost and improve the treatment of pelvic disorders. Learn more: https://www.fiercebiotech.com/medtech/renovia-raises-42m-to-fund-digital-health-solutions-for-pelvic-floor-strengthening